728 related articles for article (PubMed ID: 27573793)
21. Trastuzumab-conjugated oxine-based ligand for [
Southcott L; Wharton L; Rousseau J; Merkens H; Yang H; Bénard F; Orvig C
J Inorg Biochem; 2022 Oct; 235():111936. PubMed ID: 35878576
[TBL] [Abstract][Full Text] [Related]
22. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
23. A generic
Li N; Yu Z; Pham TT; Blower PJ; Yan R
Int J Nanomedicine; 2017; 12():3281-3294. PubMed ID: 28458546
[TBL] [Abstract][Full Text] [Related]
24. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
[TBL] [Abstract][Full Text] [Related]
25. Cyclic versus Noncyclic Chelating Scaffold for
Summer D; Garousi J; Oroujeni M; Mitran B; Andersson KG; Vorobyeva A; Löfblom J; Orlova A; Tolmachev V; Decristoforo C
Mol Pharm; 2018 Jan; 15(1):175-185. PubMed ID: 29160082
[TBL] [Abstract][Full Text] [Related]
26.
Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
[TBL] [Abstract][Full Text] [Related]
27. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
[TBL] [Abstract][Full Text] [Related]
28. Re-Evaluations of Zr-DFO Complex Coordination Chemistry for the Estimation of Radiochemical Yields and Chelator-to-Antibody Ratios of
Imura R; Ida H; Sasaki I; Ishioka NS; Watanabe S
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443566
[TBL] [Abstract][Full Text] [Related]
29. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and evaluation of novel bifunctional tetrahydroxamate chelators for PET imaging of
Rousseau J; Zhang Z; Dias GM; Zhang C; Colpo N; Bénard F; Lin KS
Bioorg Med Chem Lett; 2017 Feb; 27(4):708-712. PubMed ID: 28131709
[TBL] [Abstract][Full Text] [Related]
31.
Heskamp S; Raavé R; Boerman O; Rijpkema M; Goncalves V; Denat F
Bioconjug Chem; 2017 Sep; 28(9):2211-2223. PubMed ID: 28767228
[TBL] [Abstract][Full Text] [Related]
32. Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET.
Vosjan MJ; Perk LR; Roovers RC; Visser GW; Stigter-van Walsum M; van Bergen En Henegouwen PM; van Dongen GA
Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):753-63. PubMed ID: 21210114
[TBL] [Abstract][Full Text] [Related]
33. Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO).
Deri MA; Ponnala S; Zeglis BM; Pohl G; Dannenberg JJ; Lewis JS; Francesconi LC
J Med Chem; 2014 Jun; 57(11):4849-60. PubMed ID: 24814511
[TBL] [Abstract][Full Text] [Related]
34. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
35. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
36.
Dias GM; Ramogida CF; Rousseau J; Zacchia NA; Hoehr C; Schaffer P; Lin KS; Bénard F
Nucl Med Biol; 2018 Mar; 58():1-7. PubMed ID: 29291493
[TBL] [Abstract][Full Text] [Related]
37. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
[TBL] [Abstract][Full Text] [Related]
38. Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor β in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule.
Cai H; Shi Q; Tang Y; Chen L; Chen Y; Tao Z; Yang H; Xie F; Wu X; Liu N; Yang Y; Wu H; Tian R; Lu X; Li L
Mol Pharm; 2019 May; 16(5):1950-1957. PubMed ID: 30986347
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for (89)Zr(4+) and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice.
N Tinianow J; Pandya DN; Pailloux SL; Ogasawara A; Vanderbilt AN; Gill HS; Williams SP; Wadas TJ; Magda D; Marik J
Theranostics; 2016; 6(4):511-21. PubMed ID: 26941844
[TBL] [Abstract][Full Text] [Related]
40. A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89.
Sarbisheh EK; Salih AK; Raheem SJ; Lewis JS; Price EW
Inorg Chem; 2020 Aug; 59(16):11715-11727. PubMed ID: 32799484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
